Related Experiment Video
Updated: Mar 31, 2026
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
Sirolimus for Retinal and Uveitic Diseases
Abstract:
Chronic inflammation plays an important role in the pathogenesis of ocular diseases such as diabetic retinopathy, uveitis and age-related macular degeneration. Activation and proliferation of naïve T cells may result in pathological changes responsible for significant visual morbidity. Sirolimus (earlier termed rapamycin) is a novel drug that inhibits cellular kinases and, thereby, inhibits T-cell proliferation. Preclinical studies in experimental models have shown promising results with the use of this pharmacological agent in various ocular conditions. Subsequently, early phase I/II studies have provided encouraging safety and efficacy data. This chapter focuses on the mechanisms of action, preclinical study results and data from human clinical trials of sirolimus in human eye diseases. Key highlights from ongoing phase III clinical trials are also provided. Sirolimus, thus, appears to be an important addition to the armamentarium of steroid-sparing therapeutic agents that act on various steps in the inflammatory pathway.
Insights
Sirolimus effectively inhibits T-cell proliferation, offering a promising steroid-sparing treatment for chronic inflammatory eye diseases like diabetic retinopathy and uveitis. Clinical trials show encouraging safety and efficacy, positioning it as a valuable therapeutic option.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Chronic inflammation is a key factor in ocular diseases such as diabetic retinopathy, uveitis, and age-related macular degeneration.
- T-cell activation and proliferation contribute to pathological changes causing significant visual morbidity.
Purpose of the Study:
- To review the mechanisms of action, preclinical findings, and clinical trial data for sirolimus in treating human eye diseases.
- To highlight the potential of sirolimus as a steroid-sparing agent in ocular inflammatory conditions.
Main Methods:
- Review of preclinical studies in experimental models of ocular diseases.
- Analysis of early phase I/II human clinical trial data for safety and efficacy.
- Inclusion of key highlights from ongoing phase III clinical trials.
Main Results:
- Preclinical studies demonstrated promising results for sirolimus in various ocular conditions.
- Early phase human trials provided encouraging safety and efficacy data.
- Sirolimus demonstrates potential as a steroid-sparing therapeutic agent targeting inflammatory pathways.
Conclusions:
- Sirolimus inhibits T-cell proliferation, a crucial mechanism in managing inflammatory eye diseases.
- Clinical evidence supports the safety and efficacy of sirolimus for ocular conditions.
- Sirolimus represents a significant addition to the therapeutic options for steroid-sparing treatment of inflammatory eye diseases.
